Bio-Med Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 22-12-2024
- Paid Up Capital ₹ 1.10 M
as on 22-12-2024
- Company Age 52 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 68.42%
(FY 2023)
- Profit 132.75%
(FY 2023)
- Ebitda 3578.34%
(FY 2023)
- Net Worth 10.76%
(FY 2023)
- Total Assets 13.84%
(FY 2023)
About Bio-Med
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rajendra Garg, Saryu Garg, and Puneet Garg serve as directors at the Company.
- CIN/LLPIN
U85110UP1972PTC003542
- Company No.
003542
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 May 1972
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Ghaziabad, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Bio-Med Private Limited offer?
Bio-Med Private Limited offers a wide range of products and services, including Immunization & Vaccination Drugs, Vaccines, Medical Laboratory Instruments, Corona Test Kit, Varivax Vaccine, Alcohol Solvents, Isopropyl Alcohol IPA, Injectable Products, Botox Injection, VTM Kit.
Who are the key members and board of directors at Bio-Med?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Saryu Garg  | Managing Director | 11-May-1972 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rajendra Garg | Director | 01-Jul-2022 | Current |
| Puneet Garg | Director | 15-Dec-2005 | Current |
Financial Performance of Bio-Med.
Bio-Med Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 68.42% increase. The company also saw a substantial improvement in profitability, with a 132.75% increase in profit. The company's net worth Soared by an impressive increase of 10.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bio-Med?
In 2023, Bio-Med had a promoter holding of 95.34% and a public holding of 4.66%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bio-Med?
Unlock and access historical data on people associated with Bio-Med, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bio-Med, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bio-Med's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
